Five people aboard a tug boat are breathing a sigh of relief after being pulled to safety by the U.S. Coast Guard off the coast of La Push. Around 4:10 p.m. on Friday, the U.S. Coast Guard ...

England and the USA are set to battle it out for the services of a highly-rated Chelsea youngster. The prospect has already represented both nations at youth level and has been named in the latest ...

The English Football Association and its United States counterpart are battling for the international allegiance of the latest teenage prodigy with dual nationality, Landon Emenalo, son of former ...

Arsenal and Manchester City are at it again! This time, both Premier League giants are eyeing the same prize: Charles De Ketelaere. The 23-year-old Belgian playmaker has bounced back from a tough ...

Ryan Kent's abrupt departure from Fenerbahce has got some Rangers fans calling for the winger to make a dream return to Ibrox. The Englishman only swapped Govan for the Turkish capital at the ...

While Bavarian Nordic’s vaccine Jynneos is approved in several countries to prevent mpox and smallpox infections in adults, there has been a lack of data to support its approval in adolescents.

AUSA 2024 — The Nordic countries of Denmark, Finland, Norway and Sweden are evaluating a joint procurement of a future Infantry Fighting Vehicle (IFV), senior officials from two of the countries ...

diligence, final board approval and certain other conditions. Novelda has built a strong technology position in ultra-wideband, which is complementary to Nordic’s world leading wireless technologies.

If you hear the name “Nordic” and your mind instantly conjures up a tough-as-nails Viking, you're not alone. So if a workout move has “Nordic” in the title, it’s got to be effective ...

Nordic impact investor Summa Equity has invested ... team to guide them through each step of this momentous journey. The sale of this employee-owned company represents years of hard work, and ...

The World Health Organisation has given the Bavarian Nordic mpox vaccine the go ahead for use in adolescents aged 12 to 17, an age group which is viewed as especially vulnerable to the disease.